Literature DB >> 29487140

Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.

Kevin J Morine1, Xiaoying Qiao1, Sam York1, Peter S Natov1, Vikram Paruchuri1, Yali Zhang1, Mark J Aronovitz1, Richard H Karas1, Navin K Kapur1.   

Abstract

BACKGROUND: Heart failure is a growing cause of morbidity and mortality worldwide. Transforming growth factor beta (TGF-β1) promotes cardiac fibrosis, but also activates counterregulatory pathways that serve to regulate TGF-β1 activity in heart failure. Bone morphogenetic protein 9 (BMP9) is a member of the TGFβ family of cytokines and signals via the downstream effector protein Smad1. Endoglin is a TGFβ coreceptor that promotes TGF-β1 signaling via Smad3 and binds BMP9 with high affinity. We hypothesized that BMP9 limits cardiac fibrosis by activating Smad1 and attenuating Smad3, and, furthermore, that neutralizing endoglin activity promotes BMP9 activity.
METHODS: We examined BMP9 expression and signaling in human cardiac fibroblasts and human subjects with heart failure. We used the transverse aortic constriction-induced model of heart failure to evaluate the functional effect of BMP9 signaling on cardiac remodeling.
RESULTS: BMP9 expression is increased in the circulation and left ventricle (LV) of human subjects with heart failure and is expressed by cardiac fibroblasts. Next, we observed that BMP9 attenuates type I collagen synthesis in human cardiac fibroblasts using recombinant human BMP9 and a small interfering RNA approach. In BMP9-/- mice subjected to transverse aortic constriction, loss of BMP9 activity promotes cardiac fibrosis, impairs LV function, and increases LV levels of phosphorylated Smad3 (pSmad3), not pSmad1. In contrast, treatment of wild-type mice subjected to transverse aortic constriction with recombinant BMP9 limits progression of cardiac fibrosis, improves LV function, enhances myocardial capillary density, and increases LV levels of pSmad1, not pSmad3 in comparison with vehicle-treated controls. Because endoglin binds BMP9 with high affinity, we explored the effect of reduced endoglin activity on BMP9 activity. Neutralizing endoglin activity in human cardiac fibroblasts or in wild-type mice subjected to transverse aortic constriction-induced heart failure limits collagen production, increases BMP9 protein levels, and increases levels of pSmad1, not pSmad3.
CONCLUSIONS: Our results identify a novel functional role for BMP9 as an endogenous inhibitor of cardiac fibrosis attributable to LV pressure overload and further show that treatment with either recombinant BMP9 or disruption of endoglin activity promotes BMP9 activity and limits cardiac fibrosis in heart failure, thereby providing potentially novel therapeutic approaches for patients with heart failure.

Entities:  

Keywords:  endoglin; fibrosis; growth differentiation factor 2; heart failure; transforming growth factor beta

Mesh:

Substances:

Year:  2018        PMID: 29487140      PMCID: PMC6111008          DOI: 10.1161/CIRCULATIONAHA.117.031635

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 2.  Structural and functional characterisation of cardiac fibroblasts.

Authors:  Patrizia Camelliti; Thomas K Borg; Peter Kohl
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

3.  Hemodynamic modulation of endocardial thromboresistance.

Authors:  Navin K Kapur; Clayton B Deming; Sunil Kapur; Ce Bian; Hunter C Champion; J Kevin Donahue; David A Kass; Jeffrey J Rade
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

4.  An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Authors:  Michael S Gordon; Francisco Robert; Daniela Matei; David S Mendelson; Jonathan W Goldman; E Gabriela Chiorean; Robert M Strother; Ben K Seon; William D Figg; Cody J Peer; Delia Alvarez; Bonne J Adams; Charles P Theuer; Lee S Rosen
Journal:  Clin Cancer Res       Date:  2014-09-26       Impact factor: 12.531

5.  A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Authors:  Fatima H Karzai; Andrea B Apolo; Liang Cao; Ravi A Madan; David E Adelberg; Howard Parnes; David G McLeod; Nancy Harold; Cody Peer; Yunkai Yu; Yusuke Tomita; Min-Jung Lee; Sunmin Lee; Jane B Trepel; James L Gulley; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2015-06-08       Impact factor: 5.588

6.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Authors:  Leah Iles; Heinz Pfluger; Lisa Lefkovits; Michelle J Butler; Peter M Kistler; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

Review 7.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

8.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

9.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.

Authors:  Lu Long; Mark L Ormiston; Xudong Yang; Mark Southwood; Stefan Gräf; Rajiv D Machado; Matthias Mueller; Bernd Kinzel; Lai Ming Yung; Janine M Wilkinson; Stephen D Moore; Kylie M Drake; Micheala A Aldred; Paul B Yu; Paul D Upton; Nicholas W Morrell
Journal:  Nat Med       Date:  2015-06-15       Impact factor: 53.440

10.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

Authors:  Ankur Gulati; Andrew Jabbour; Tevfik F Ismail; Kaushik Guha; Jahanzaib Khwaja; Sadaf Raza; Kishen Morarji; Tristan D H Brown; Nizar A Ismail; Marc R Dweck; Elisa Di Pietro; Michael Roughton; Ricardo Wage; Yousef Daryani; Rory O'Hanlon; Mary N Sheppard; Francisco Alpendurada; Alexander R Lyon; Stuart A Cook; Martin R Cowie; Ravi G Assomull; Dudley J Pennell; Sanjay K Prasad
Journal:  JAMA       Date:  2013-03-06       Impact factor: 56.272

View more
  19 in total

1.  MiR-208b/miR-21 Promotes the Progression of Cardiac Fibrosis Through the Activation of the TGF-β1/Smad-3 Signaling Pathway: An in vitro and in vivo Study.

Authors:  Yifan Zhang; Bo Yuan; Yue Xu; Na Zhou; Ruiqi Zhang; Lan Lu; Zhanbin Feng
Journal:  Front Cardiovasc Med       Date:  2022-07-05

2.  Endothelial Activin Receptor-Like Kinase 1 (ALK1) Regulates Myofibroblast Emergence and Peritubular Capillary Stability in the Early Stages of Kidney Fibrosis.

Authors:  Carlos Martínez-Salgado; Fernando Sánchez-Juanes; Francisco J López-Hernández; José M Muñoz-Félix
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 3.  Smad-dependent pathways in the infarcted and failing heart.

Authors:  Claudio Humeres; Harikrishnan Venugopal; Nikolaos G Frangogiannis
Journal:  Curr Opin Pharmacol       Date:  2022-03-31       Impact factor: 4.768

4.  Heart failure: BMP9 is an inhibitor of cardiac fibrosis.

Authors:  Alexandra Le Bras
Journal:  Nat Rev Cardiol       Date:  2018-03-15       Impact factor: 32.419

5.  Chronic peripheral ghrelin injection exerts antifibrotic effects by increasing growth differentiation factor 15 in rat hearts with myocardial fibrosis induced by isoproterenol.

Authors:  Q Ren; P Lin; Q Wang; B Zhang; L Feng
Journal:  Physiol Res       Date:  2019-12-19       Impact factor: 1.881

6.  Myeloid interleukin-4 receptor α is essential in postmyocardial infarction healing by regulating inflammation and fibrotic remodeling.

Authors:  Jianrui Song; Ryan A Frieler; Steven E Whitesall; Yutein Chung; Thomas M Vigil; Lindsey A Muir; Jun Ma; Frank Brombacher; Sascha N Goonewardena; Carey N Lumeng; Daniel R Goldstein; Richard M Mortensen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-08       Impact factor: 4.733

7.  Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling.

Authors:  Rajvir Singh; Ravinder K Kaundal; Baoyin Zhao; Rihab Bouchareb; Djamel Lebeche
Journal:  Pharmacol Res       Date:  2021-01-29       Impact factor: 7.658

8.  Exogenous BMP9 promotes lung fibroblast HFL-1 cell activation via ALK1/Smad1/5 signaling in vitro.

Authors:  Yaqun Wang; Xiaonan Sima; Ying Ying; Yonghong Huang
Journal:  Exp Ther Med       Date:  2021-05-04       Impact factor: 2.447

Review 9.  Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?

Authors:  Jan Frohlich; Manlio Vinciguerra
Journal:  Geroscience       Date:  2020-10-06       Impact factor: 7.713

10.  Melatonin promotes the BMP9-induced osteogenic differentiation of mesenchymal stem cells by activating the AMPK/β-catenin signalling pathway.

Authors:  Tianyuan Jiang; Chao Xia; Xiaoting Chen; Yan Hu; Yan Wang; Jin Wu; Shuyan Chen; Yanhong Gao
Journal:  Stem Cell Res Ther       Date:  2019-12-21       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.